Effects of guanidinoacetic acid and creatine monohydrate supplementation on markers of health and cognitive function

Effects of 12 weeks of guanidinoacetic acid and creatine monohydrate supplementation during an exercise and diet intervention on markers of health and cognitive function in older adults

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66268301

Enrollment

200

Registered

2025-11-17

Start date

2025-09-08

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Guanidinoacetic Acid (GAA) supplementation with and without Creatine Monohydrate (CrM) on markers of cognitive function and health in older adults. Other

Interventions

Participants will be randomized (using Stratified Randomization using sealed envelopes) into one of the three treatment groups listed below. Treatment 1. Exercise/Diet + Guanidinoacetic Acid Place

Treatment 2. Exercise/Diet + Guanidinoacetic Acid (2 x 1 g/d) + Placebo (2 x 5 g/d maltodextrin)

Treatment 3. Exercise/Diet + Guanidinoacetic Acid (2 x 1 g/d) + Creatine Monohydrate (2 x 5 g/d). The GAA, CrM and placebo (maltodextrin) supplements will be prepared in labeled stick packs for dou

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or female between the ages of 45 and 75 years. 2. Participant is willing to comply with the study procedures. 3. Participant is willing to refrain from alcohol intake and use of non-steroidal anti-inflammatory drugs (NSAIDS), aspirin, and other over-the-counter (OTC) pain medications for 48-hours prior to each testing session. 4. Participant is willing to complete the study based on the duration of the individual visits and scheduling requirements. 5. Participant is willing to comply and understand the cognitive function tests.

Exclusion criteria

Exclusion criteria: 1. Participant has a known vitamin B12/B6 or folate deficiency. 2. Participant has known homocystinuria. 3. Participant has high homocysteine levels. 4. Participant has a history of kidney disease requiring dialysis. 5. Participant has diagnosed cognitive impairment or neurological disease. 6. Participant is pregnant, breastfeeding, or wishing to become pregnant during the study. 7. Participant has uncontrolled heart disease, hypertension, diabetes, thyroid disease, cancer, neurological disease, or medically treated major psychological or depressive disorder that may affect results of the study. 8. Participant has a known allergy to meat or fish, GAA, CrM, or Maltodextrin.

Countries

United States of America

Contacts

Public ContactChristopher Rasmussen

crasmussen@tamu.edu9794581741

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026